tcsc6566 Nexopamil racemate

Nexopamil racemate is the racemate of Nexopamil. Nexopamil is a combined Ca²⁺/5-HT₂ antagonist on thrombus formation in vivo and on platelet aggregation in vitro.

IC50 & Target: Ca²⁺/5-HT₂^[1]

In Vitro: Serotonin-induced platelet aggregation in dog platelet-rich plasma (PRP) in vitro is most potently inhibited by Nexopamil (IC₅₀ 81 nM) ^[1].

In Vivo: Nexopamil (0.05 mg/kg) completely abolishes cyclic flow reductions (CFRs) during the first 30 min after application without significantly altering hemodynamics^[1].